De Preter Katleen, Pattyn Filip, Berx Geert, Strumane Kristin, Menten Björn, Van Roy Frans, De Paepe Anne, Speleman Frank, Vandesompele Jo
Center for Medical Genetics, Ghent University Hospital 1K5, De Pintelaan 185, 9000 Gent, Belgium.
BMC Genomics. 2004 Feb 3;5(1):11. doi: 10.1186/1471-2164-5-11.
Activation of proto-oncogenes by DNA amplification is an important mechanism in the development and maintenance of cancer cells. Until recently, identification of the targeted genes relied on labour intensive and time consuming positional cloning methods. In this study, we outline a straightforward and efficient strategy for fast and comprehensive cloning of amplified and overexpressed genes.
As a proof of principle, we analyzed neuroblastoma cell line IMR-32, with at least two amplification sites along the short arm of chromosome 2. In a first step, overexpressed cDNA clones were isolated using a PCR based subtractive cloning method. Subsequent deposition of these clones on a custom microarray and hybridization with IMR-32 DNA, resulted in the identification of clones that were overexpressed due to gene amplification. Using this approach, amplification of all previously reported amplified genes in this cell line was detected. Furthermore, four additional clones were found to be amplified, including the TEM8 gene on 2p13.3, two anonymous transcripts, and a fusion transcript, resulting from 2p13.3 and 2p24.3 fused sequences.
The combinatorial strategy of subtractive cDNA cloning and array CGH analysis allows comprehensive amplicon dissection, which opens perspectives for improved identification of hitherto unknown targeted oncogenes in cancer cells.
原癌基因通过DNA扩增激活是癌细胞发生和维持的重要机制。直到最近,靶向基因的鉴定还依赖于劳动强度大且耗时的定位克隆方法。在本研究中,我们概述了一种简单有效的策略,用于快速全面地克隆扩增和过表达的基因。
作为原理验证,我们分析了神经母细胞瘤细胞系IMR-32,其在2号染色体短臂上至少有两个扩增位点。第一步,使用基于PCR的消减克隆方法分离过表达的cDNA克隆。随后将这些克隆点样到定制微阵列上,并与IMR-32 DNA杂交,从而鉴定出因基因扩增而过表达的克隆。使用这种方法,检测到了该细胞系中所有先前报道的扩增基因的扩增情况。此外,还发现另外四个克隆被扩增,包括位于2p13.3的TEM8基因、两个未知转录本以及一个由2p13.3和2p24.3融合序列产生的融合转录本。
消减cDNA克隆和阵列比较基因组杂交分析的组合策略能够全面剖析扩增子,为更好地鉴定癌细胞中迄今未知的靶向癌基因开辟了前景。